Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

140.990
+1.6001.15%
Volume:1.01M
Turnover:141.41M
Market Cap:68.40B
PE:34.28
High:141.260
Open:140.770
Low:139.180
Close:139.390
52wk High:269.118
52wk Low:133.350
Shares:485.15M
Float Shares:483.95M
Volume Ratio:0.55
T/O Rate:0.21%
Dividend:4.20
Dividend Rate:2.98%
EPS(TTM):4.113
EPS(LYR):8.878
ROE:6.66%
ROA:6.58%
PB:2.55
PE(LYR):15.88

Loading ...

Australian shares rise in earnings-heavy session; CSL plunges 18%

Reuters
·
Feb 11

Update: CSL Posts Lower Fiscal H1 Underlying Earnings, Revenue; Reaffirms Fiscal 2026 Outlook; Shares Hit Eight-Year Low

MT Newswires Live
·
Feb 11

BUZZ-Australia's CSL tumbles to near 8-year low after CEO retires, HY profit slips

Reuters
·
Feb 11

Australian biotech firm CSL tanks 17% after CEO departure, weak first-half earnings

Reuters
·
Feb 11

Stock Track | CSL Plummets 9.15% Intraday on Disappointing Earnings and CEO Departure

Stock Track
·
Feb 11

Former 'market-darling' CSL dumps CEO as it reports results

Switzer
·
Feb 11

CSL loses $10 billion in Trump vaccine crossfire

The West Australian
·
Feb 11

CSL Posts Fiscal H1 Underlying EPS of $4.03 Vs FactSet Estimate of $4.12, Revenue of $8.33 Billion Vs FactSet Estimate of $8.49 Billion

MT Newswires Live
·
Feb 11

Australia's CSL posts a 7% drop in first-half profit

Reuters
·
Feb 11

BRIEF-CSL Declares Interim Dividend Of $1.30 Per Share

Reuters
·
Feb 11

CSL Ltd - Performance of CSL Vifor Will Continue to Be Adversely Impacted by Generic Competition in Iron Products

THOMSON REUTERS
·
Feb 11

CSL Ltd - CSL Behring, Second-Half Growth Is Expected to Be Driven by Ig, Albumin and Newly Launched Products

THOMSON REUTERS
·
Feb 11

CSL Ltd - Share Buy-Back Expanded From US$500M to US$750M

THOMSON REUTERS
·
Feb 11

CSL H1 Net Income USD 401 Million VS. Ibes Estimate USD 1,936 Million

THOMSON REUTERS
·
Feb 11

CSL Ltd - Maintains Its Guidance for 2026 Financial Year

THOMSON REUTERS
·
Feb 11

Asia Morning Call-Global Markets

Reuters
·
Feb 11

Australia's CSL turns to ex-vaccine division head after CEO McKenzie retires

Reuters
·
Feb 10

Australian biotech firm CSL says CEO Paul McKenzie to retire

Reuters
·
Feb 10

BRIEF-CSL Says Paul Mckenzie Retires As CEO, Gordon Naylor Appointed Interim CEO

Reuters
·
Feb 10

CSL Ltd - Paul Mckenzie Will Retire as Managing Director

THOMSON REUTERS
·
Feb 10